Cholangiocarcinoma

C. sinensis can effectively promote the pathogenesis of CCA and significantly increase the expression of CCA-related genes (e.g., CK19 and CK7). The inflammation, disrupting circadian rhythms and altering energy metabolism caused by C. sinensis infection, may promote the progression of CCA. This study provides a foundational experimental basis for diagnosing and intervening in C. sinensis-related CCA.

P=N/A, N=60, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2027 --> May 2027

P2/3, N=400, Recruiting, RenJi Hospital | Phase classification: P=N/A --> P2/3

The presentation of intrahepatic cholangiocarcinoma (ICC) often masquerades as a pyogenic liver abscess. Therefore, atypical imaging features on multimodal studies, together with markedly elevated levels of Gamma-glutamyl Transpeptidase (GGT), Alkaline Phosphatase (ALP) and Carbohydrate antigen 19-9 (CA19-9), must alert clinicians to the possibility of underlying malignancy to prevent diagnostic delay.

Subsequently, the gain of expression of mesenchymal marker vimentin in tumor cells revealed the induction of EMT in the sgP19/kRAS model, and it is induced by activating the TGFβ/ZEB1 signaling pathway. Altogether, the study suggests that TGFβ/ZEB1 mediates the induction of EMT in iCCA, while targeting EMT failed to inhibit iCCA development or tumor metastasis, disputing the claims that EMT is a major molecular event leading to tumor metastasis.

Our findings suggest that long-term exposure to TGF-β1 triggers the malignant transformation of cholangiocytes by activating EMT and fibrosis, as well as IL-6/STAT3-mediated proliferation signaling.

P1, N=55, Active, not recruiting, University of Southern California | Trial completion date: Dec 2025 --> Jul 2026

P1/2, N=103, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended

P2, N=50, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Aug 2026

This study aims to elucidate the role of microRNAs in regulating metabolic pathways in HCC by delineating numerous miRNA-target interactions involved in glycolysis, lipid, amino acid, and nucleotide metabolism. This knowledge will enable us to identify novel diagnostic biomarkers and therapeutic targets for prognosis and to explore effective novel precision treatment strategies.

These findings suggest that tinengotinib might have activity in patients with cholangiocarcinoma with FGFR2 fusions that progressed following FGFR inhibitor therapy. Anti-tumour activity was also observed in patients with other FGFR alterations. The data from this phase 2 study supported the initiation of a phase 3 registration trial.